Low concentration of sodium tetradecyl sulfate and hypertonic glucose solution for the treatment of telangiectasia: A prospective randomized clinical trial.
Telangiectasias
hypertonic glucose
sclerotherapy
sodium tetradecyl sulfate
Journal
Phlebology
ISSN: 1758-1125
Titre abrégé: Phlebology
Pays: England
ID NLM: 9012921
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
pubmed:
31
7
2023
medline:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
This study aimed to compare telangiectasias disappearance after sclerotherapy with hypertonic glucose (HG) and different concentrations of sodium tetradecyl sulfate (STS). Women aged 18-70 years with telangiectasias were included. The primary efficacy endpoint was telangiectasia disappearance. The clearing of vessels was assessed using a six-point scale (from 0 to 5). A total of 116 women completed an 8-week follow-up: 31, 27, 25, and 33 were in the HG 75%, STS 0.05%, STS 0.1%, and STS 0.15% groups, respectively. The median score of vein disappearance was significantly lower in the STS 0.05% (3, 0.25-4), STS 0.1% (3, 1.25-4), and STS 0.15% (4, 2-4) groups than in the HG group (4, 3-5) after 56 days, Sclerotherapy of telangiectasias with 75% HG showed significantly better results than low concentrations of STS. ClinicalTrials.gov NCT04132323.
Identifiants
pubmed: 37519033
doi: 10.1177/02683555231191969
doi:
Banques de données
ClinicalTrials.gov
['NCT04132323']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
622-627Déclaration de conflit d'intérêts
Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.